-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Psoriasis is a relatively common and serious skin disease.
The biological agent gusecumumab is a fully humanized monoclonal antibody targeting interleukin 23, which can inhibit interleukin 23 and effectively relieve silver.
Soriasis , the drug is currently approved for the treatment of moderate to severe plaque psoriasis
.
This article uses twoPhase III trials of 1-year data ( DISCOVER-1 and 2-DISCOVER ) , assessment of Gousse library monoclonal antibody therapy safety psoriatic arthritis (PsA) is
Psoriasis is a relatively common and serious skin disease.
The study included active PsA patients (n = 1120; DISCOVER-1 in addition to using TNFi outer 118 patients , the remaining patients had not received biologic therapy) , Patients were randomly divided into three groups: 1) every 4 Week (Q4W) subcutaneous injection of 100 mg of Gusecumumab ; 2 ) Subcutaneous injection of 100 mg of Gusecumumab in the 0th week, 4th week and every 8 weeks (Q8W) thereafter ; 3) Placebo treatment
.
At week 24 , patients in the placebo group were switched to gusecumumab 100mg Q4W .
The study included active PsA patients (n = 1120; DISCOVER-1 in addition to using TNFi outer 118 patients , the remaining patients had not received biologic therapy) , Patients were randomly divided into three groups: 1) every 4 Week (Q4W) subcutaneous injection of 100 mg of Gusecumumab ; 2 ) Subcutaneous injection of 100 mg of Gusecumumab in the 0th week, 4th week and every 8 weeks (Q8W) thereafter ; 3) Placebo treatment
Week 24 when , in the placebo group and Gousse library monoclonal antibody group (Q4W + Q8W) adverse event incidence fairly
.
AEs were 142.
8/100PY sand 150.
6/100PY s , severe AEs were 7.
1/100PY sand 4.
Week 24 when , in the placebo group and Gousse library monoclonal antibody group (Q4W + Q8W) adverse event incidence fairly
The main adverse reactions of gucuzenumab in the treatment of PsA
The main adverse reactions of gucuzenumab in the treatment of PsA The main adverse reactions of gucuzenumab in the treatment of PsAIt can be seen that PsA patients can tolerate gusecumumab 100mg Q4W and Q8W well
.
Gousse library monoclonal antibody treatment of PsA safety of psoriasis and consistent
It can be seen that PsA patients tolerate Gusecumumab 100mg Q4W and Q8W well to PsA patients .
Original source:
Original source: Original source:Proton Rahman.
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.
J Rheumatol.
September 2021.
Proton Rahman.
Leave a message here
